Buprenorphine (Sandoz) TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: buprenorphine
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 5 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 5 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 5 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 5 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 5 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 5 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 10 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 10 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 10 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 10 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 10 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 10 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 15 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 15 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 15 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 15 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 15 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 15 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 20 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 20 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 20 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 20 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 20 micrograms/hour transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Drug delivery system, transdermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted (in black ink) with "Buprenorphinum 20 micrograms/h" on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 1 pack
- 2 pack
- 4 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 25 micrograms/h transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Patch, dermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side, and pale yellowish-brown adhesive foil imprinted in black ink with Buprenorphinum 25 ug/h on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 2 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 30 micrograms/h transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Patch, dermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side, and pale yellowish-brown adhesive foil imprinted in black ink with Buprenorphinum 30 ug/h on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 2 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Brand name
(ARTG)
: BUPRENORPHINE SANDOZ buprenorphine 40 micrograms/h transdermal drug delivery system sachetDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
BUPRENORPHINE SANDOZ patches are indicated for the management of severe pain where: · other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and · the pain is opioid-responsive, and · requires daily, continuous, long-term treatment. BUPRENORPHINE SANDOZ patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPRENORPHINE SANDOZ patches are not indicated as an as-needed (PRN) analgesia.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Patch, dermal
- Transdermal
- Rectangular transdermal patch with rounded edges having transparent release liner on bottom side and pale yellowish-brown adhesive foil imprinted in black ink with Buprenorphinum 40 ug/h on upper side
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicines require authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
- 2 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems